Loading...
•
Dec 31, 2020
Acadia Healthcare Q4 2020 Earnings Report
Acadia Healthcare's financial performance was reported for Q4 2020, revealing revenue growth and strategic progress.
Key Takeaways
Acadia Healthcare reported a revenue increase in Q4 2020 compared to the previous year, driven by solid volumes and strong cost management in their U.S. operations. However, the company experienced a net loss due to discontinued operations related to the sale of their U.K. business.
Revenue from continuing operations increased to $541.3 million, compared to $501.2 million in Q4 2019.
Net loss attributable to Acadia stockholders was $783.7 million, or $8.78 per diluted share, due to a loss from discontinued operations.
U.S. same facility revenue increased by 7.6% compared to Q4 2019.
The company closed on the sale of its U.K. operations to Waterland Private Equity in January 2021.
Acadia Healthcare
Acadia Healthcare
Forward Guidance
Acadia provided financial guidance for the full year and first quarter of 2021, excluding discontinued operations and the impact of future transactions.
Positive Outlook
- Revenue in a range of $2.23 billion to $2.28 billion
- Adjusted EBITDA in a range of $490 million to $520 million
- Adjusted earnings per diluted share in a range of $2.20 to $2.45
- Operating cash flows in a range of $250 million to $285 million
- Addition of approximately 300 beds to existing facilities and 170 beds through new facilities
Challenges Ahead
- Interest expense of approximately $80 to $85 million
- A tax rate of approximately 26.5%
- Depreciation and amortization expense in a range of $105 million to $110 million
- Stock compensation expense of approximately $28 million
- Total capital expenditures in a range of $285 million to $325 million